NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I appreciate your asking the question. I do not see it the way you do.  The halt would be at the discretion of FINRA, on the OTC and they disfavor halts on that exchange.

Requesting a halt, or at least exploring whether one could be obtained, would not show panic. It would show prudence. A company preparing to disclose highly material clinical trial results at a public scientific conference has every reason to think about market-order issues around that disclosure.

The key distinction is that NWBO traded OTC, not on Nasdaq or NYSE. For listed stocks, FINRA explains that companies notify the listing exchange before releasing material news, and the listing exchange decides whether to halt trading. FINRA specifically lists product-related information as the kind of news that may justify a halt.

But OTC securities are different. FINRA Rule 6440 says FINRA may direct members to halt trading and quotations in OTC equity securities only in specified circumstances, including foreign regulatory halts, derivative halts, or extraordinary-event halts. FINRA’s supplementary material also says FINRA does not favor imposing OTC trading halts and will use that authority only in very limited circumstances.

So the criticism that NWBO “should simply have halted trading” is too simplistic. A Nasdaq or NYSE issuer has a normal exchange-halt process for pending material news. An OTC issuer is in a more constrained position. The company can ask, alert, or try to create a record, but the actual halt authority sits with FINRA under a narrower OTC framework.

That means if Linda Powers requested a halt, it does not show she “didn’t know the rules” or “panicked.” It may show the opposite: she wanted the record to show the company sought an orderly market before releasing major trial data, even though OTC halt relief was difficult. That is not panic. That is prudence.

And the NYAS collapse did not happen in a neutral information environment. Feuerstein immediately pushed the “failure” narrative. That narrative was cited broadly enough that even some cancer-awareness sources reportedly repeated it before later removing it once the underlying claims were recognized as inaccurate. Yet the original publication did not, as far as I have seen, issue a meaningful correction or retraction. That matters because these narratives do not just describe market action; they can help create it.

And the data were not a failure. The results were later peer-reviewed and published in JAMA Oncology, showing a statistically significant overall-survival benefit. So turning a halt request into evidence of panic gets the issue backwards.

The more serious question is why positive clinical data could be presented publicly and then immediately reframed as failure while the stock was being crushed. I would not call that panic by NWBO. I would call it evidence that NWBO was trying to manage a major announcement in a hostile OTC environment where trading mechanics, short narratives, and media framing were all part of the battlefield.